Skip to main content
. Author manuscript; available in PMC: 2020 Nov 23.
Published in final edited form as: J Cardiopulm Rehabil Prev. 2020 May;40(3):174–177. doi: 10.1097/HCR.0000000000000459

Table 1.

Participant Characteristicsa

Variable BB
n = 59
NBB
n = 115
AP
n = 174
P value
BB Versus NBB
Age, yr 70.7 ± 6.8 70.9 ± 7.4 70.8 ± 7.2 .892
Sex
 Female, % 70.3 82.4 78.6
Race
 White, % 85.9 75.4 78.6
 Other, % 14.1 24.6 21.4
Body mass, kg 83.9 ± 16.1 81.8 ± 17.4 82.5 ± 17 .457
BMI, kg/m2 30.9 ± 4.7 30.6 ± 5.8 30.7 ± 5.4 .637
NYHA class, %
 I 0 0.7 0.5
 II 67.2 69.7 68.9
 III 32.8 29.6 30.6
HTN, %
 Yes 92.2 78.2 82.5
DM, %
 Yes 18.8 15.5 16.5
Blood pressure, mm Hg
 Systolic 147 ± 19.7 142.0 ± 17 143.9 ± 18.1 .058
 Diastolic 81.8 ± 9.7 81.5 ± 10.1 81.6 ± 10.0 .846
Medications, %
 Diuretics 55.3 64.5 62.8
 ARB 15.8 9.5 10.6
 ACE 44.7 51.5 50.2
 CCB 31.6 29.0 29.5
 Nitrates 21.1 20.1 20.3
 Aspirin 44.7 37.9 39.1
 Digoxin 23.7 32.5 30.9

Abbreviations: ACE, angiotensin-converting enzyme inhibitor; AP, all participants; ARB, angiotensin receptor blocker; BB, participants with β-blocker therapy; BMI, body mass index; CCB, calcium-channel blockers; DM, diabetes mellitus; HTN, hypertension; NBB, participants with no β-blocker therapy; NYHA, New York Heart Association.

a

Values are mean ± SD or n (%).